XML 89 R64.htm IDEA: XBRL DOCUMENT v3.25.4
COMMITMENTS AND CONTINGENCIES (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 28, 2025
USD ($)
Dec. 22, 2022
USD ($)
quarterly_payment
Feb. 10, 2021
Apr. 17, 2019
Dec. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2020
Jun. 30, 2021
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Other Commitments [Line Items]                          
Change in excess firm purchase commitment liability                     $ 0 $ 2,100 $ 1,500
Research and development                     62,359 37,652 63,079
Contract cost incurred in research and development activities                     82,600    
Charge for purchase of IPR&D asset                     12,807 0 0
Siegfried Evionnaz SA                          
Other Commitments [Line Items]                          
Cost of purchased minimum quantity product         $ 800           800    
Excess firm purchase commitment charge                     800 3,600  
Patheon | Vafseo Drug Product                          
Other Commitments [Line Items]                          
Purchase commitment, option for non-auto renewal, prior written notice period (in months)                 18 months        
Minimum purchase commitment         1,100           1,100    
STA Pharmaceutical Hong Kong Limited                          
Other Commitments [Line Items]                          
Excess firm purchase commitment charge                     69,200    
WuXi STA                          
Other Commitments [Line Items]                          
Excess firm purchase commitment charge                     1,800    
Purchase commitment, option to extend, prior notice period (in months)     18 months                    
Long-term purchase commitment, option to terminate, prior notice period (at least)     180 days                    
BioVectra Inc                          
Other Commitments [Line Items]                          
Long-term purchase commitment, termination amount payable   $ 32,500                      
Long-term purchase commitment, upfront payment termination amount   $ 17,500                      
Long-term purchase commitment, termination amount payable after upfront payment, number of quarterly periods | quarterly_payment   6                      
Long-term purchase commitment, termination amount payable after upfront payment, per quarter   $ 2,500                      
Long-term purchase commitment, termination amount payable after upfront payment   $ 15,000                      
Long-term purchase commitment, imputed interest on termination amount payable   17.00%                      
Long-term purchase commitment, upfront termination amount classified as cost of goods sold   $ 11,200                      
Amortization discount                     300 1,600 1,900
Panion & BF Biotech, Inc | License Agreement                          
Other Commitments [Line Items]                          
License agreement, notice period for termination       90 days                  
Royalty payments                     $ 11,300 9,100 $ 10,000
Cyclerion | License Agreement                          
Other Commitments [Line Items]                          
Expiration period beginning with first commercial sale (in years)                     10 years    
Termination period, prior written notice (in days)                     180 days    
Cyclerion | License Agreement | Acquired Licenses                          
Other Commitments [Line Items]                          
Upfront payments                   $ 3,000      
Cyclerion | License Agreement | Acquired Licenses | Research and development                          
Other Commitments [Line Items]                          
Upfront payments               $ 3,000          
Cyclerion | Cyclerion Amendment | Acquired Licenses                          
Other Commitments [Line Items]                          
Upfront payments           $ 500 $ 1,250            
Specified development and regulatory milestone payments, contingent on a product-by-product basis                     $ 197,500    
Research and development         $ 1,000                
Cyclerion | Cyclerion Amendment | Acquired Licenses | Maximum                          
Other Commitments [Line Items]                          
Tiered royalties (as percent)         20.00%           20.00%    
Cyclerion | Cyclerion Amendment | Acquired Licenses | Research and development                          
Other Commitments [Line Items]                          
Upfront payments                       1,250  
Contingent consideration                       $ 500  
Cyclerion | Cyclerion Amendment | Acquired Licenses | Accrued Liabilities                          
Other Commitments [Line Items]                          
Contingent consideration                     $ 1,000    
Q32 | Q32 Asset Purchase Agreement                          
Other Commitments [Line Items]                          
Upfront payments $ 12,800                        
Specified development and regulatory milestone payments, contingent on a product-by-product basis 94,500                        
Upfront payment 7,000                        
Additional upfront payment $ 3,000                   3,000    
Additional payment term 6 months                        
Development milestone payment $ 2,000                   2,000    
Commercial milestone payment 487,500                        
Asset acquisition, consideration transferred, transaction cost $ 800                        
Charge for purchase of IPR&D asset                     $ 12,800